Development group (n = 260) | Validation group(n = 133) | p | |
---|---|---|---|
Age (year) | 45 ± 12 | 45 ± 13 | 0.571 |
Gender (male/female) | 222/38 | 108/25 | 0.310 |
Red blood cell count (× 1012/L) | 3.93 ± 0.91 | 3.88 ± 0.95 | 0.620 |
White blood cell count (×109/L) | 8.08 ± 3.56 | 9.43 ± 7.78 | 0.058 |
Hemoglobin (g/dL) | 119.92 ± 23.35 | 118.58 ± 22.86 | 0.587 |
Albumin (g/L) | 31.76 ± 4.54 | 31.42 ± 4.32 | 0.469 |
Alanine aminotransferase (U/L) | 707.38 ± 877.45 | 649.70 ± 855.85 | 0.534 |
Prothrombin activity (%) | 29.28 ± 7.57 | 27.87 ± 7.84 | 0.085 |
INR | 2.75 ± 1.00 | 3.05 ± 1.27 | 0.019 |
Creatinine (μmol/L) | 78.27 ± 44.77 | 85.84 ± 70.73 | 0.262 |
Total bilirubin (μmol/L) | 378.86 ± 168.36 | 376.05 ± 158.08 | 0.871 |
TC (mmol/L) | 2.44 ± 1.31 | 2.42 ± 1.05 | 0.849 |
TG (mmol/L) | 0.86 ± 0.52 | 0.96 ± 0.51 | 0.056 |
HDLC (mmol/L) | 0.19 ± 0.18 | 0.18 ± 0.17 | 0.546 |
LDLC (mmol/L) | 1.10 ± 0.60 | 1.06 ± 0.65 | 0.568 |
MELD scores, median (IQR) | 25.98 (23.13, 29.4) | 26.46 (24.16, 31.19) | 0.055 |
Ascites (yes/no) | 167/93 | 95/38 | 0.175 |
mortality (yes/no) | 77/183 | 37/96 | 0.726 |